chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report was received from the patient's mother and refers to a 89 year old female patient. The patient did not have any known drug reactions or allergies. There was no information's about her concurrent conditions or medical history provided. On an unknown date approximately in 2007, (reported as "10 years ago" and also reported as "either in 2010 or 2011"), the patient was vaccinated with a dose of ZOSTAVAX to prevent shingles (dose, route of administration, anatomical location, lot# and expiration were not reported). On an unknown date, the patient experienced normal pressure hydrocephalus, non specific codes lymphoma, hyperthyroidism, high blood pressure and incontinence. The patient received unspecified high blood pressure and thyroid medicine as a treatment. On unknown date in 2009, (reported as "8 years ago"), the patient experienced shingles. On 09-JAN-2017 (reported as "today"), the patient had culture test done and was diagnosed with shingles again. The patient sought unspecified medical attention and received unspecified treatment for shingles. Product quality complaint (PQC) was not reported. The outcomes of events were not reported. Causality assessment was not provided. Upon internal review, the events of normal pressure hydrocephalus, non specific codes lymphoma and hyperthyroidism were determined to be medically significant. Additional information is not expected as there was no consent to contact with the patient's physician.
Pt vaccinated with DTP/OPV cried for several hrs (6hrs), high pitched cry.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 61-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 05Apr2021 as dose 1, single (Lot number: ER8737), in left arm and on 26Apr2021 as dose 2, single (Lot number: ER8735) at the age of 60 years, in left arm for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), on 16Nov2021 as dose 3 (booster), single (Lot number: 069F21A), in left arm for covid-19 immunisation. The patient had no relevant medical history. The patient had no known allergies. Concomitant medication(s) included: LEXAPRO; ZYRTEC [CETIRIZINE HYDROCHLORIDE]. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Unknown results, notes: COVID 19 Treatment; (unspecified date) Negative, notes: receiving a negative test; (30May2022) Positive, notes: tested positive for COVID. Therapeutic measures were taken as a result of vaccination failure, covid-19 with Paxlovid.
Pregnant; This spontaneous prospective pregnancy case was reported by a physician and describes the occurrence of EXPOSURE DURING PREGNANCY (Pregnant) in a 31-year-old female patient (gravida 1) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037K20A) for COVID-19 vaccination.     Concurrent medical conditions included Seasonal allergy since January 2007. Concomitant products included ADAPALENE, BENZOYL PEROXIDE (EPIDUO) from 05-Dec-2020 to 30-Jan-2021 for Acne, FLUTICASONE PROPIONATE (FLONASE [FLUTICASONE PROPIONATE]) and CETIRIZINE for Allergy, PRENATAL VITAMINS [ASCORBIC ACID;BETACAROTENE;CALCIUM SULFATE;COLECALCIFEROL;CYANOCOBALAMIN;FERROUS FUMARATE;FOLIC ACID;NICOTINAMIDE;PYRIDOXINE HYDROCHLORIDE;RETINOL ACETATE;RIBOFLAVIN;THIAMINE MONONITRATE;TOCOPHERYL ACETATE;ZINC OXIDE] for Pregnancy.   On 26-Dec-2020 at 12:00 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Jan-2021 at 9:00 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. The patient's last menstrual period was on 20-Nov-2020 and the estimated date of delivery was 28-Aug-2021. On 26-Dec-2020, the patient experienced EXPOSURE DURING PREGNANCY (Pregnant). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  fifth week of the pregnancy.  On 26-Dec-2020, EXPOSURE DURING PREGNANCY (Pregnant) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 18-Dec-2020, Pregnancy test: positive (Positive) Positive. On 09-Feb-2021, Chromosome analysis normal: normal (normal) normal. On 09-Feb-2021, Ultrasound abdomen: normal (normal) normal.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Estimated date of conception was on 05-DEC-2020 There were no complications or acute illnesses during this pregnancy till date
Patient was given 0.5ml instead of 0.25 ml booster vaccine. Patient was called on 1.19/22 and denies any problems since vaccination. Letter also sent tell patient dosage given.
I successfully  and correctly injected the 1st of pediatric pfizer covid vaccination on 12/19/21 around 12:29pm to the patient. Patient appeared to be fine. I asked the patient to sit down for 15 minutes to observe any possible side effects. Patient was about to leave around 12:45pm after waited 15 minutes, however fainted while walking through the OTC section. Patient was conscious and breathing. we helped him to sit in the chair. I checked his vital signs, everything appeared to be normal. He told me he felt a little short of breath (may due to nervousness) after the vaccination, however, he did not tell anyone. When he fainted he felt he could not breath and just "blacked out". I gently checked his head as he hit his head on the floor when fainted. there was  a little bump on the head where hit the floor, however, no blood or bruises seen. We observed the patient on the chair for another 15 minutes or more, he appeared to be normal . I offered water and tyelnol for the pain, however, the mother already purchased some tylenol OTC and did not think the patient need it at that moment. Patient and the family left the pharmacy afterwards.
fever, chills, body aches, headache, loss of appetite. lasted for 30 hours
Headache, Myalgia, Fever, NauseaVomiting, Fatigue, Chills. Narrative:
Blotches appeared on face and arms the morning after nasal vaccine. Became short of breath and heartbeat became rapid. See by physician which diagnosed as mild allergic reaction to H1N1 nasal vaccine. Medication was prescribed but had to be changed on 11/12/09. Child is fine now 11/16/09.
pt recv vax & devel soreness @ the inj site, irritability & a low grade fever which cont to 26SEP98 & then resolved;5OCT98 pt devel rash, diarrhea, irritability & fever of 100.4;6OCT98 pt hosp;on admission WBC count was 12.7;mild anemia;
I experienced body aches, fever, chills, and went I arrived home the fever increased to 105.1. I called emergency number and in the ambulance on the way to the hospital it was 101.3.  My fever was still at 101.3 after the doctor took my temperature after two hours hours of waiting.  I was experiencing low oxygen, weak, abdominal pain, and vomiting.  I still have a sore throat and a runny nose.
Patient described soreness/numbness/tightness along left jaw line extending toward ear. Patient elected to try an ice pack and rest.
Following the injection, client reported feeling faint, sweaty and numbness in hands. Client appears diaphoretic and pale.  Client was sat on the floor in the recovery position. Initial vitals: 100/55, 97,98% O2.   Second set of vitals @05:05pm: 111/51, 73, 20, 98%.  Reassessment @ 5:15pm: calm, breathing at 18 breaths per min.  Remained for further observation sitting upright in chair for additional 15 minutes. Discharge set of vitals @ 5:36pm: 120/72, 16, 60 99%.  Departed clinic on his own accord.
Scaly plaque type lesion on face about the diameter of a pea.; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EP7534) via an unspecified route of administration in the left arm on 17Mar2021 at 20:00 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. Medical history included post concussion syndrome and cephalgia. The patient had allergies to food, medications, or other products (not specified). Concomitant medications included melatonin (MANUFACTURER UNKNOWN) started on an unknown date for unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 31Mar2021, the patient experienced scaly plaque type lesion on face about the diameter of a pea. The treatment received for the adverse event was not reported. The clinical outcome of the event scaly plaque type lesion on face was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
One of the nurses asked me to look at a bag that contained one vial of VAQTA and PNEUMOVAX 23 to make a point that they look very similar. With the TWINRIX shortage we are using more VAQTA and recently went to single dose PNEUMOVAX 23 the vials are very similar in shape and color.
Patient refers to begin "itching" on the left side of the neck, acne and redness that was irradiating to the neck, upper extremities, abdomen and inguinal area.
Patient came to clinic to receive a Pfizer Bivalent Booster. After medical staff checked to make sure Patient was cleared to receive vaccine Patient and Patients mother were given all information about vaccine and care recommended for after. Patient and her mother confirmed Patient was getting Pfizer Bivalent. Patient was nervous and while calming patient I grabbed the wrong vaccine. Mistake was found when checking the count for the day.
Round red "rash" appearing spots on chest, abdomen and both arms, fever, malaise started 24 hours ago, swollen lymph nodes under left arm, tender to touch, 2cm x 2cm pustual at injection site.
Pharmacist gave the Fluzone HD to a 57 yr old patient. The patient did not speak English and the pharmacist was not able to use interpreter service because this event happened when the pharmacist was running an Immunization event.
This spontaneous report as received from a medical assistant refers to a female patient of unknown age. Pertinent medical history, concurrent conditions and drug reactions were unknown by the reporter. On 15-AUG-2011, the patient was vaccinated with a dose of M-M-R II, 0.5 ml, subcutaneously, lot number 0155AA, expiration date 01-FEB-2013, (Anatomical location was not provided). No other suspect or concomitant medication were reported. On an unknown date after receiving M-M-R II, the patients titers came back negative (antibody test negative). The patient sought medical attention by contacting a medical office an stated "she needs another shot". The outcome of the event and the causality between the therapy with M-M-R II and the event were unknown. Additional information has been requested.
Patient developed localized redness & swelling on right thigh (siTe for Pediarix + Prevnar-13 vaccines were given) 31 hours after vaccines were given treated with ice pack & Infant's Tylenol 2.5ml every 4 hours as needed.
Dizziness, Headache, Arthralgia, Fever, lightheaded, no appetite, palpitations, chills, tired Narrative:
Less than 24 hours after shot awoke with extreme dizziness, became increasingly sever and hours later threw up several times and could not function.  911 called, vitals checked and nothing identified.  Have continuing dizziness that is not like vertigo. Lightheaded and drowsy inhibiting function.
Approximatley 3 weeks after my second vaccine dose, I experienced a sudden onset of stiffness, weakness, joint pain, and limited range of motion in fingers of right hand, including bouts of involuntary index finger contraction.  I have no history of arthritis, degenerative  disease, nerve damage, or injury .  I'm still experiencing the symptoms two months later, and they have not improved or worsened.
Numb ankles and toes, left and right, heaviness in lower legs.  PT and chiropractor treatments??NO HELP
Patient reported developing a rash all over body the next day after receiving vaccine. She said that it was spreading.
Nurse reported 4-month-old twins received first dose of ROTATEQ; This spontaneous report was received from a registered nurse, referring to a 4-months-old patient of unknown gender. The patient's medical history, concurrent conditions, and concomitant therapies were not reported.  On 05-OCT-2023, the patient was vaccinated with the first dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) oral liquid, 1 dose, administered orally, lot # reported as X001085 with expiration date on 01-NOV-2024), for prophylaxis (inappropriate schedule of product administration).  Lot number X001085 is an invalid lot number for rotavirus vaccine, live, oral, pentavalent (ROTATEQ).  This is one of two cases received from the same reporter.; Sender's Comments:  US-009507513-2310USA001641:
Information has been received from a physician concerning a 19 year old male patient who on 14-OCT-1994 and on 04-MAR-1997 was vaccinated with the first and second dose of MMR II. On 03-JAN-2010 the patient experienced right parotitis and was diagnosed with mumps the same day. At the time of the report, the patient's outcome was unknown. Follow-up information was received which reported that on 09-JAN-2010 (reported as 03-JAN-2010 previously) the patient developed right parotitis and right facial swelling. It was unknown if the patient experienced orchitis. On 11-JAN-2010, the patient was diagnosed with mumps. The patient had blood work performed on 18-JAN-2010. At the time of the report, the patient's outcome was unknown. No further information is available.
1 DAY after flu immunization area LUA - Red - got worse, hot too touch & tender too touch.
COVID-19; COVID-19; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 68-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), in Apr2022 as dose number unknown, single (Batch/Lot number: unknown) at the age of 67 years for covid-19 immunization. The patient had no relevant medical history. The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 2022, outcome "unknown" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (2022) Positive. Therapeutic measures were taken as a result of drug ineffective, covid-19 with paxlovid in Jul2022.  Clinical course: The patient had no known allergies. patient received any other medications with in 2weeks was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Intense pain in upper arm, not injection site, nausea, almost fainting. Arm sore periodically 10/22/2020
pt recvd vax 11MAY94 & 13MAY94 devel red painful rash on lt arm
high fever  to 102.8    extreme diarrhea and urine of yellow color not seen before    no balance, couldn't walk  symptons started going away 9-3 evening except diarrhea
This spontaneous report as received from a doctor of pharmacy refers to a patient of unknown age and gender. Pertinent medical history and drug reactions/allergies were not reported. On 21-AUG-2013, the patient was vaccinated with ZOSTAVAX (lot # J002777 and expiry date 12-JUL-2014) (dose and route were not reported). No concomitant medication was reported. The call was reported originally on 04-NOV-2013 in which the reporter requested the stability for an improperly stored ZOSTAVAX. At the time of the call it was reported that the ZOSTAVAX was exposed to 15F for an unspecified amount of hours but reported that no doses of ZOSTAVAX were administered. The reporter called back again on 05-NOV-2013, and stated that he thought that the ZOSTAVAX might had been stored improperly since May 2013 and that the temperature of the ZOSTAVAX had ranged between 15f and 20F for an unspecified amount of hours. At that time the reporter was unsure if the ZOSTAVAX was administered but stated that he thought the ZOSTAVAX would have been administered. On further investigation, the pharmacist reported that ZOSTAVAX had been improperly stored since about 10-OCT-2013 reaching a highest of 20F for a total time of 600 hours. It was reported that the patient had no adverse effect. Further investigation stated that the pharmacist had determined that this case might involve approximately 5 different Lots of ZOSTAVAX (details unspecified) stored improperly at temperatures up to 21F. He stated the time frame for the excursions would be as of the day each of the ZOSTAVAX Lots was received at his facility through the date of patient administration, which he believed might had been months, dating back to on an unknown date in May 2013. These involved approximately 40 patients. He had no specific breakdown of time frame as his record didn't indicate when he received each Lot but he was calling further for the data. He also could not identify, at this time, which Lot # was administered on which date. Pharmacist would call back after he had compiled all of the necessary information and would like revaccination recommendations for any excursion that could not be supported. Pharmacist stated there had been no adverse effects noted by any of the patients. The pharmacist faxed a spreadsheet which included the 38 patients names, the date of administration as well as the lot and expiration dates of the ZOSTAVAX which was unsupported an administrated. This is one of several reports from the same source. Additional information has been requested.
headache, fever, Temp 103-104 x 3wks. Saw family MD. Rec. medication for fever. After fever normal (3wks) began having eye & mouth gestures. Saw neurologist, hosp. 3 days for testing. No seizures. Motor tics.
Pt arrived to receive the moderna vaccine, prior to administration pt was asked a series of questions with question 1 being have you ever received a covid vaccine in the past. Pt stated "No" At this time medication was prepped and given and pt waited 15 minutes with no issues noted. I was later putting the vaccine in and it noted pt received the Jansen vaccine 4/10/2021. I immediately contact pt to verify if in fact they had received this vaccine that was noted on web site. Pt stated she had not received the vaccine and was not sure why is was noted. At this time I did reach out to  discuss the above noted event. All information provided and waited for response back. Dr. was notified of the event and no other vaccine needed. Did also speak with patient and they finally did admit to getting the vaccine and and that they had lied and they had not received it because of the information that had been released about side effects of J&J vaccine after getting it. We are reporting event per request but no noted adverse effects noted.
Dizziness, headache, body  aches, increased heart rate with activity , fatigue, brain fog. Ordered meclizine and propanolol and rest and  to follow up with primary care. Completed follow up with primary care next day due to symptoms worsening.  To follow up with primary care if symptoms not resolved by 4 days. Blood work completed and normal. Medications help manage symptoms.   Symptoms not worsened today, but have not resolved. Have also had ringing in ears. Will follow up with primary care on Monday for further instructions.
Client came into clinic on 3/18/15 with mother and brother. Clts left arm had some redness and indentation just under the muscle to the inner side of the arm close to the body. Also faint bruising on muscle just above indentation. Clt. states swelled up and became very painful and bruised approximately 4-5 days after administration. Clt was advised to be evaluated by physician.
This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (Headache) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 027C21A and 003C21A) for COVID-19 vaccination. No Medical History information was reported. On 18-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 15-Jun-2021, the patient experienced HEADACHE (Headache). At the time of the report, HEADACHE (Headache) outcome was unknown. Concomitant product use was not provided by the reporter. Treatment information was not provided.
pt recv vax 17JUL97 & 27JUL97 pt exp gen rash w/50-100 lesions on arm, legs & back as well as pruritus;
rt upper arm became reddened, blotchy w/in 15-20min p/vax;
I started getting symptoms of a headache, congestion, sinus and nasal issues, cough, post nasal drip, fever, and aches and pains. I had a positive COVID-19 test. I was prescribed molnupiravir. I feel like the medication did help. My symptoms lasted for 5 days strong then lingered on like a sinus infections with fatigue. I still have tiredness and fatigue.
Pfizer-BioNTech COVID-19 VACCINE EUA; Throat swelling/closing up; SOB, dizziness 15 min post injection; lasting about 5 min but dizziness remains
a severe nosebleed; a severe nosebleed with clotting; This is a spontaneous report from a contactable consumer. This consumer reported for a female patient (daughter). A female patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection. Batch/Lot number was not reported), dose 2 via an un-specified route of administration on an unspecified date as DOSE 2, SINGLE for COVID-19 immunization. The patient medical and concomitant medication history were reported. It was mentioned that, just wanted to update about a reaction patient had that was associated with recent vaccination. Patient (my daughter) had a severe nosebleed with clotting after second COVID19 vaccination. The outcome of the events were unknown.  The lot number was not provided. Information on lot number has been requested during follow up.